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AIM
To assess the quality of and to critically synthesize the
available data on hepatitis C infections in the Middle
East and North Africa (MENA) region to map evidence
gaps.
METHODS
We conducted an overview of systematic reviews
(SRs) following an a priori developed protocol
(CRD42017076736). Our overview followed the preferred
reporting items for systematic reviews and metaanalyses guidelines for reporting SRs and abstracts and
did not receive any funding. Two independent reviewers
systematically searched MEDLINE and conducted a
multistage screening of the identified articles. Out of
5758 identified articles, 37 SRs of hepatitis C virus (HCV)
infection in populations living in 20 countries in the MENA
region published between 2008 and 2016 were included
in our overview. The nine primary outcomes of interest
were HCV antibody (anti-) prevalences and incidences
in different at-risk populations; the HCV viremic (RNA
positive) rate in HCV-positive individuals; HCV viremic
prevalence in the general population (GP); the prevalence
of HCV co-infection with the hepatitis B virus, human

Conflict-of-interest statement: The authors have declared that
no competing interests exist.
PRISMA 2009 Checklist statement: The authors have read the
PRISMA 2009 Checklist, and the manuscript was prepared and
revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this
work non-commercially, and license their derivative works on
different terms, provided the original work is properly cited and
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript

WJG|www.wjgnet.com

3038

July 21, 2018|Volume 24|Issue 27|

Chaabna K et al . HCV in the MENA region
© The Author(s) 2018. Published by Baishideng Publishing
Group Inc. All rights reserved.

immunodeficiency virus, or schistosomiasis; the HCV
genotype/subtype distribution; and the risk factors for
HCV transmission. The conflicts of interest declared by
the authors of the SRs were also extracted. Good quality
outcomes reported by the SRs were defined as having
the population, outcome, study time and setting defined
as recommended by the PICOTS framework and a
sample size > 100.

Core tip: To achieve hepatitis C virus (HCV) infection
elimination goals by 2030, precise prevention strategies
targeting specific populations at higher risk of acquiring
HCV infection and treatment programs require the
development of evidence-based health policies. HCV
infection epidemiology in the countries of the Middle
East and North Africa was characterized in 37 systematic
reviews (SR) during the last decade. Our systematic
overview critically analyzes and synthesizes the findings
of these SRs to map the evidence gaps in the region.
Additionally, we assessed the quality of the reported
outcomes and documented conflicts of interest of the
SR authors who disclosed financial relationships with
pharmaceuticals.

RESULTS
We included SRs reporting HCV outcomes with different
levels of quality and precision. A substantial proportion of
them synthesized data from mixed populations at differing
levels of risk for acquiring HCV or at different HCV
infection stages (recent and prior HCV transmissions).
They also synthesized the data over long periods of time
(e.g. , two decades). Anti-HCV prevalence in the GP varied
widely in the MENA region from 0.1% (study dates not
reported) in the United Arab Emirates to 2.1%-13.5%
(2003-2006) in Pakistan and 14.7% (2008) in Egypt.
Data were not identified for Bahrain, Jordan, or Palestine.
Good quality estimates of anti-HCV prevalence in the GP
were reported for Algeria, Djibouti, Egypt, Iraq, Morocco,
Pakistan, Syria, Sudan, Tunisia, and Yemen. Anti-HCV
incidence estimates in the GP were reported only for
Egypt (0.8-6.8 per 1000 person-year, 1997-2003). In
Egypt, Morocco, and the United Arab Emirates, viremic
rates in anti-HCV-positive individuals from the GP were
approximately 70%. In the GP, the viremic prevalence
varied from 0.7% (2011) in Saudi Arabia to 5.8%
(2007-2008) in Pakistan and 10.0% (2008) in Egypt.
Anti-HCV prevalence was lower in blood donors than
in the GP, ranging from 0.2% (1992-1993) in Algeria
to 1.7% (2005) in Yemen. The reporting quality of
the outcomes in blood donors was good in the MENA
countries, except in Qatar where no time framework
was reported for the outcome. Some countries had
anti-HCV prevalence estimates for children, transfused
patients, contacts of HCV-infected patients, prisoners,
sex workers, and men who have sex with men.
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INTRODUCTION
In 2017, the World Health Organization estimated that
71 million people suffer from chronic hepatitis C virus
[1]
(HCV) infection worldwide . In 2015, HCV infection
[1]
resulted in 399000 deaths , predominantly from
complications such as liver cirrhosis and hepatocellular
[1,2]
carcinoma (HCC) . Egypt had the largest iatrogenic
transmission of blood-borne pathogens in the general
[3]
population (GP) worldwide . The use of parenteral
anti-schistosomiasis therapy in Egypt, extensively
practiced with poor sterile techniques since the 1920s,
is considered to be the leading cause of the dramatic
[3]
increase in the human HCV reservoir in the GP . In
Egypt, HCV antibody (anti-) prevalence was estimated
[4]
[5]
to be 15% in 2008 and 6% in 2014 . Globally,
Pakistan has the second largest number of people with
[6]
viremic HCV infection, after China . Due to the high
burden of HCV infection in Egypt and Pakistan, the
MENA region has been identified as the region most
affected region by HCV worldwide.
Our primary objective was to assess the quality of
the data reported by the published systematic reviews
(SRs) of HCV epidemiology in MENA countries taking
into account conflict of interest disclosed by the authors
of these SRs. Secondarily, we aimed to critically analyze
all data reported by the SRs to map evidence gaps and
to report a comprehensive synthesis.

CONCLUSION
A substantial proportion of the reported outcomes may
not help policymakers to develop micro-elimination
strategies with precise HCV infection prevention and
treatment programs in the region, as nowcasting HCV
epidemiology using these data is potentially difficult.
In addition to providing accurate information on HCV
epidemiology, outcomes should also demonstrate
practical and clinical significance and relevance. Based
on the available data, most countries in the region
have low to moderate anti-HCV prevalence. To achieve
HCV elimination by 2030, up-to-date, good quality data
on HCV epidemiology are required for the GP and key
populations such as people who inject drugs and men
who have sex with men.
Key words: Hepatitis C; meta-research; risk factors;
incidence; genotype; Middle East and North Africa;
systematic review; Micro-elimination; Pakistan; Gulf
Cooperation Council
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We conducted an overview of SRs based on the Cochrane
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[7]

Handbook for Systematic Reviews of Interventions .
This overview is part of the Population Health
Publications Assessment Project that aims to assess the
methodological quality of published SRs on population
health issues in the MENA region. The ultimate goal of
[8]
this meta-research (i.e., research on research ) is to
evaluate and contribute to the improvement of population
[9]
health research practices in the MENA region .
An a priori protocol was registered with the
International Prospective Register of Systematic Reviews
[10]
(PROSPERO registration number CRD42017076736) .
We report this overview according to the standards
set out in the preferred reporting items for syste
matic reviews and meta-analyses (PRISMA) 2009
[11-13]
[11,12]
guidelines
. PRISMA checklists for SRs
and
[13]
abstracts
are reported as Supplementary Materials 1
and 2, respectively. We also assessed the methodological
quality of our overview using the Assessment of Multiple
[14]
Systematic Reviews (AMSTAR) tool . The AMSTAR
checklist is provided as Supplementary Material 3.

HCV transmission. Additionally, we extracted conflicts of
interest reported by the SR authors.

Literature search and data management

Two reviewers (AA and HA) independently and
systematically searched the Medical Literature Analysis
and Retrieval System Online (MEDLINE) through the
[16]
search engine PubMed
using broad search criteria
(Supplementary Material 4). The search criteria,
limited to reviews, systematic reviews, and metaanalysis, identified 5758 reviews (Figure 1). After
removing duplicate publications of the same reviews
[17]
with Endnote , title/abstract screening and then fulltext screening were conducted by AA and HA with
[18,19]
Rayyan software
. Discrepant inclusions of SRs were
discussed by AA, HA, and KC under the supervision of the
senior authors. We eventually included 37 SRs of HCV
infection in MENA countries (Figure 1). The characteristics
of these included SRs are described in Supplementary
Material 5. Data extraction was conducted by AA and KC
and crosschecked for accuracy.

Inclusion and exclusion criteria

Conflicts of interest

We included all SRs (publication date: January 2008 to
December 2016) of HCV infection related to the countries
in the MENA region published in peer-reviewed journals
since 2008, the publication year of the first version
of the Cochrane Handbook for Systematic Reviews of
[7]
Interventions . We included MENA countries where
Arabic, English, French, and/or Urdu are the primary
official languages and/or the medium of instruction in the
colleges/universities. These languages are those spoken
by the authors of this overview.

We recorded the conflicts of interest reported by the SR
authors who disclosed financial relationships. An asterisk
(*) was inserted next to the outcomes reported by SRs
with at least one author who disclosed direct or indirect
financial relationships with Gilead Science, AbbVie,
Merck, Bristol-Myers Squibb, or Janssen Therapeutics.
In 2013, Gilead Science launched sofosbuvir-based
regimens to cure chronic infections with HCV genotypes
[20]
1, 2, 3, and 4 (viremic cases) that made elimination
of HCV infection achievable for the first time. A large
proportion of patients (> 90%) treated with sofosbuvir
associated with another direct-acting antiviral drug (DAA)
[21]
demonstrated a sustained virological response . The
recommended regimens and treatment durations differ
according to the HCV genotype infection. Additionally,
[21]
sofosbuvir-based regimens appear to be relatively safe .
However, cases of cardiac events have been reported
when sofosbuvir-based treatments were administered in
[22,23]
combination with amiodarone and/or propranolol
.
Since then, new DAAs have been developed by other
pharmaceuticals (AbbVie, Merck, Bristol-Myers Squibb,
[24]
and Janssen Therapeutics) .

Population of interest

Our population of interest was the population living in
the following 20 countries: Algeria, Bahrain, Djibouti,
Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco,
Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Sudan,
Syria, Tunisia, the United Arab Emirates (UAE), and
Yemen. These selected MENA countries have a combined
population of over 560 million people, accounting for
[15]
approximately 8% of the world’s population . We
excluded SRs of HCV infection in populations from
countries outside the MENA region and SRs with military
personnel who were based in the MENA region but not
from the region.

Quality assessment and conflict of interest

Primary outcomes

Good quality outcomes reported by the SRs were defined
as having the population, outcome, timing, and setting
[25,26]
defined as recommended by the PICOTS framework
(intervention and comparator being irrelevant in our
[27]
overview) and a sample size > 100 . A maximum score
of six was given to the outcome if the following measures
were included: (1) Population profile, such as pregnant
women and patients under hemodialysis; (2) the method
used for the outcome estimation, such as meta-analysis
or weighted average; (3) the data collection period; (4)
the study geographic location; (5) the number of studies;

We extracted the following variables: Anti-HCV
prevalence and incidence in different at-risk populations,
HCV viremic rates in HCV positive individuals, and HCV
viremic prevalence in the GP. Viremic infection represents
the presence of HCV in the bloodstream detected
with polymerase chain reaction (HCV RNA-positive).
We also extracted the prevalence of co-infection with
HBV (hepatitis B surface antigen, HBsAg), human
immunodeficiency virus (HIV), or schistosomiasis; HCV
genotype/subtype distributions; and risk factors for
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Records identified through
database searching
(n = 5758)

Additional records identified
through other sources
(not applicable)

Eligibility

Screening

Records after duplicates removed
(n = 11)

Records screened
(n = 5747)

Records excluded
(n = 5086)

Full-text articles assessed
for eligibility
(n = 661)

Full-text articles excluded,
2
with reasons
(n = 624)

1

Included

Systematic reviews included
in qualitative synthesis
(n = 37)

Systematic reviews included in
quantitative synthesis (meta-analysis)
(Not applicable)

Figure 1 PRISMA 2009 Flow diagram describing the selection of the systematic reviews reporting hepatitis C outcomes in our systematic overview.
Reasons of exclusion: 1Systematic reviews were excluded from the overview because they did not meet our inclusion criteria; 2Not a systematic review (n = 116), no
hepatitis C outcomes (n = 472), not a polulation from MENA (n = 34), duplicate (n = 1), and publication in Portuguese (n = 1).

and (6) a total sample size > 100.

sexually transmitted infections; healthcare workers;
barbers; contacts of HCV-infected patients; people who
inject drugs (PWID); prisoners; sex workers; and men
who have sex with men (MSM) (Tables 1-3). We took
financial disclosures into account when assessing and
[31]
reporting these outcomes . Whenever two outcomes
describing the same population in the same country
had the same quality score, we reported the outcome
extracted from the SR the authors of which disclosed
no financial relationship with HCV DAA pharmaceutical
companies.

Synthesis

We narratively synthesized the data on HCV infection in
each of the 20 MENA countries in at-risk populations.
We defined the GP as individuals from the community
who are not in any specific population category such
as blood donors or outpatients. More specifically, we
reported HCV epidemiology in the GP separately from
that in blood donors. Blood donors are selected healthy
populations that may not be representative of the
[28,29]
GP
. Therefore, if a SR reported an outcome for the
GP including specific population categories, we reported
this GP specifying all the included population categories.
Extracted data from the included SRs were compiled
into evidence tables. We reported anti-HCV prevalence
in at-risk populations from the SRs and the quality
assessment of the reported prevalence (Supplementary
Materials 6 and 7). Country-level anti-HCV prevalence
was classified into low (< 1.5%), moderate (1.5%-3.5%),
[30]
and high (> 3.5%) levels . If available, we also
reported the viremic rate in anti-HCV positive individuals
and the viremic prevalence in the GP.
For each country, we mapped evidence gaps with
the most up-to-date anti-HCV prevalence with the best
quality assessment (highest quality assessment score)
in the GP; blood donors; pregnant women; children;
patients on dialysis; hemophiliac, thalassemic, and
transfused patients; patients with HCC, acute liver
disease, chronic liver disease (CLD), HIV and/or other

WJG|www.wjgnet.com

RESULTS
Quality assessment - PICOTS framework

Only six out of 37 SRs of HCV epidemiology in the
MENA region published after 2008 conducted a quality
[6,27,32-35]
assessment of the studies included
. HCV
prevalence or incidence is meaningful only when the
population, the outcome, the study setting, and the study
[25]
period are stated (PICOTS framework) . Additionally, for
SRs, reporting the quantitative synthesis method used
and the number of studies included in the synthesis as
[11-13]
recommended by PRISMA guidelines
is critical to
enable the assessment of the quality of the outcome (Tables
1-3). Some SRs failed to precisely report the methodology
[36-38]
they used for their quantitative synthesis
.
In addition to providing a time framework for mor
bidity measurements, reporting the collection period
for HCV prevalence is essential because changes in
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Table 1 Hepatitis C antibody prevalence evidence gap mapping with quality assessment, North Africa and Pakistan
Algeria

Djibouti

Egypt

Libya

Morocco

Sudan

Tunisia

Pakistan

0.2%
(1992-1993)1
0.6% (2008)1

0.3%
(1998-2000)1
No data

0.9%-6.6%
(1992-2001)1
0.4%-2.3% (-)3

0.2%-0.8%
(2005-2011)1
1.0% (-)2

0.0%-1.3%
(2005-2007)1
0.6% (2006)1

0.1%-0.9%
(2000-2010)1
0.2% (2006)1

Children

No data

No data

No data

No data

No data

No data

0.2%-8.6%
(2000-2006)1
5.3%
(2001-2006)1
1.7% (-)2

Hemodialysis, renal dialysis,
and/or dialysis patients
Hemophiliac or other
bleeding disorder patients
Transfused patients

39.0% (-)3

No data

30.0%
(2010-2011)2
No data

No data

1.7%-16.8%
(2006-2009)1
8.6%-12.7%
(-)3
2.1%-5.8%
(2002-2005)1
46.1%-100%
(2002-2009)1
No data

32.3%
(2009-2010)1
No data

8.5%-23.7%
(2005-2010)1
13.0% (2008)2

14.6%-32.6%
(2000-2002)1
55.7% (-)2

No data

No data

10.8%
(1999-2001)1
No data

No data

Thalassemic patients

No data

No data

No data

No data

No data

68.3%-76.0%
(-)3
57.3%
(2003-2006)2
0.0% (1999)1

4.7%
(2008-2009)1
6.1% (-)2

Patients with hepatocellular
carcinoma
Patients with acute liver
disease
Patients with chronic liver
disease
Healthcare workers

11.1%-81.6%
(2000-2008)1
19.5%-69.6%
(2000-2010)1
85.9%
(1997-2004)1
No data

54.1%-68.3%
(2003-2004)1
2.3%-42.4%
(1981-2006)1
No data

No data

No data

No data

No data

No data

No data

No data

Barbers

No data

No data

12.3% (-)3

2.0%-6.8%
(1992-2001)1
No data

Contact of patients with
hepatitis C
People who inject drugs

No data

No data

No data

No data

No data

No data

63.0% (-)2

94.2% (2010)1

Prisoners
Patients with HIV and/or
other sexually transmitted
infection
Sex workers

No data
No data

No data
No data

No data
No data

23.7% (2006)1
44.9%-54.1%
(2003)1

No data

No data

No data

Men who have sex with men

No data

No data

No data

5.2%-7.3%
(2010-2011)1
No data

Blood donors
Pregnant women

No data

No data
No data

73.7%
(1983-1986)2
No data
1.1%-5.0%
(2001-2007)1
No data
22.9%-79.2%
(2010-2012)1
No data
5.4%
(2006-2010)1
No data
No data

11.0%
(1996-1998)1
6.3% (2007)2
No data
0.0%
(2005-2007)1
No data

19.0%-63.5%
(1982-< 1995)2
8.0%-48.0%
(< 1995)3
80.5%
(2005-2008)2
1.0% (2005)1
No data

No data

No data

No data

21.7%-29.1%
(2009-2012)1
No data
35.5%
(1997-2006)1

No data
1.7%
(2010-2012)1
0.0%-5.1%
(2011-2012)1
0.0%-5.9%
(2011-2012)1

38.8%
(2003-2005)1
25.0%-56.0%
(2000-2002)1
13.2%-15.4%
(2002)1
36.2-56.8%
(1999-2003)1
53.7% (-)2
No data
0.0%-86.6%
(2000-2005)1
5.6%-6.0%
(2001-2002)1
No data
4.3%-38.0%
(2000-2004)1
57.0% (-)2
No data
No data

1.1% (2007)1

No data

No data

No data

Prevalence, year of data collection. 1Good quality; 2Average quality; 3Poor quality.

risk factors for HCV were demonstrated over time
[39]
in Egypt and other countries . Out of the 29 SRs
reporting the anti-HCV prevalence, 16 (55%) failed to
accurately report the years during which data collection
[32,34,36-38,40-50]
occurred
. Thirteen SRs did not report the
[34,36-38,40-48]
data collection years at all
, two reported the
publication year as or instead of the data collection period
[32,49]
of the study
, and one SR published in 2011 stated
“unless indicated the estimates were for 2004 because
[50]
of lack of more recent data” . The choice of this year,
i.e., 2004, was not justified and appears arbitrary. For
instance, the authors reported an anti-HCV prevalence
in individuals with sexually transmitted diseases (STD)
in Saudi Arabia of 15.9%* in 2004, as no year was
[50]
indicated . Remarkably, the actual study that estimated
the prevalence in individuals with STDs in Saudi
[51]
Arabia reported 1990 as the year of data collection .
Additionally, we identified SRs pooling the prevalence
measured over a long time period such as a pooled
[52]
estimate for 1982-2010 in Tunisia
or for 1989-2012
[27]
in Sudan . These estimates that encompass long time
periods do not reflect changes in prevalence over time
and do not accurately describe the past and current HCV

WJG|www.wjgnet.com

epidemiology in a population.
[50,53]
Similarly, for genotype distribution, only two
[6,27,33,37,38,40,43-45,48-50,53-58]
of the 18 SRs
reported HCV
[50]
genotype/subtype distributions, and one
of the 12
[27,39,40,44,45,50,52,53,57,59-61]
SRs
reported risk factors with
the data collection year provided, which would be an
indicator if changes in genotype/subtype geographical
distributions or in risk factors occurred over time. However,
[33,48,50,52,59,61]
regarding incidence, six SRs
identified data
points, and all of them reported the data collection years
as those provided by the included studies.
Regarding the definitions of populations, we
identified SRs pooling anti-HCV prevalences from
populations at differing risk levels for acquiring HCV
[27,33,37,41,52,59,62,63]
infections
. We question the meaningfulness
of these estimated outcomes for mixed populations. How
would clinicians and policymakers interpret and use an
estimated anti-HCV prevalence for a mixed population
including, for instance, patients with lymphoproliferative
disorders, prisoners, patients with depression, mothers,
[41]
and sex workers ? Regarding the GP, we identified
[27,33,52,59,62]
SRs that combined blood donors with the GP
.
Healthy blood donors (voluntary and non-remunerated)
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Table 2 Hepatitis C antibody prevalence evidence gap mapping with quality assessment, Arab Peninsula
Bahrain

Kuwait

Blood donors

No data

Pregnant women

No data

0.8%-1.2%
(nationals)
(2002)
5.4%-13.5%
(migrants)
(2002)1
No data

Children

No data

Hemodialysis, renal
dialysis, and/or
dialysis patients
Hemophiliac or other
bleeding disorder
patients
Transfused patients
Thalassemic patients
Patients with
hepatocellular
carcinoma
Patients with acute
liver disease
Patients with chronic
liver disease
Healthcare workers
Barbers
Contact of patients
with hepatitis C
People who inject
drugs
Prisoners
Patients with HIV
and/or other sexually
transmitted infection
Sex workers
Men who have sex
with men

Oman

Qatar

Saudi Arabia

0.4%-0.7%
1.1% (nationals and
0.0%-5.6% (nationals
(2006-2011)1 migrants) 0.5%(nationals) and migrants, 1988-2009)
(-)2
0.4%-4.2% (nationals,
1990-2009) 0.0%-34.0%
(migrant, 1990-2002)1

United Arab
Emirates

Yemen

0.5%-1.1%
(2004-2009)1

1.7% (2005)1

13.0%-13.4%
(migrants)
(1994-1996)1
No data

3.3%-8.5%
(2011)1

No data

No data

0.1%-4.6% (1989-2002)1

No data

No data

No data

0.7%-1.8% (1989-2002)1

9.2% (-)3

27.0%-71.0%
(1992-1995)1

26.5% (1991)1

44.6% (-)2

14.7%-78.2% (1995-2008)1

24.4%
(1991-1993)1

2.1%
(2007-2009)1
40.0%-62.7%
(1997-2013)1

60.0% (1992)2

No data

No data

No data

78.6% (-)3

No data

No data

No data
No data

No data
No data

No data
No data

4.6%-78.6% (1990-2011)1
12.7%-70.0% (1990-2000)1

No data

No data

48.5% (2006-2008)1

No data
18.8%
(1990-2001)2
No data

No data
No data

No data

No data
33.0%
(1965-1995)1
No data

No data

No data

No data

No data

3.4%-40.7% (2000-2005)1

No data

37.8% (-)2

No data

29.4 (2000-2005)1

11.9%-65.0% (1989-2004)1

No data
No data
No data

0.9% (-)2
No data
No data

0.0% (-)2
No data
No data

No data
No data
No data

0.0%-0.3% (2001-2005)1
No data
0.0%-1.6% (-)2

No data

No data

48.1% (2011)1

No data

No data
No data

No data
0.9%(2012)1

No data
No data

No data
No data

No data
No data

No data
No data

28.4%-38.2%
(2001-2010)1

1.2%
(2006-2007)1
43.7% (-)2

6.4%-8.8%
(1997-1999)1
33.8% (-)3
1.1%-3.5% (-)3
No data
No data

14.4%-54.7% (1995-2004)1

No data
No data
27.0%
(1994-1996)1
No data

No data
No data

No data
12.0%-15.9% (1985-2010)1

No data
No data

No data
No data

No data
No data

No data
No data

No data
No data

No data
No data

No data

Prevalence, year of data collection. 1Good quality; 2Average quality; 3Poor quality.

recruited with selection programs likely have lower
[64]
anti-HCV prevalence than the GP . Hence, in SRs
pooling blood donor estimates with the GP estimates,
the pooled estimates likely underestimate the actual
anti-HCV prevalence in the GP. Furthermore, as metaanalyses give greater weight to studies with higher
sample sizes and the sample sizes of studies describing
anti-HCV prevalence in blood donors are often large,
these pooled anti-HCV prevalences are more likely to
be underestimated. In a country such as Djibouti where
there were no identified studies reporting in the GP and
only one identified study reporting on blood donors,
reporting the estimate in blood donors as the lower limit
[6]
of possible anti-HCV prevalence in the GP might be
[35]
relevant because of the scarcity of data. Riou et al
used that estimate to provide an adjusted estimate for
the GP. We believe that in countries where data points
among the GP are available, blood donors should be

WJG|www.wjgnet.com

excluded.
Similarly, for reported genotype/subtype distributions
and risk factors, mixing populations limited the ability to
analyze that data in-depth.

Conflict of interest

Out of the 37 SRs included in our overview, 32 SRs
had authors who disclosed no conflict of interest. In
[65]
one SR , authors disclosed financial support from a
US National Science Foundation Graduate Research
Fellowship, a Sigma Xi Grant-in-Aid of Research, and
the Global Health Program at the University of Michigan
[6,34,50,56]
School of Public Health. Four SRs
reported
at least one author who disclosed a direct or indirect
financial relationship with pharmaceutical companies;
among these SRs, three reported financial support from
[6,50,56]
[6]
HCV DAA pharmaceutical companies
. Gower et al
reported indirect financial support from Gilead Science,
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Table 3 Hepatitis C antibody prevalence evidence gap mapping with quality assessment, Fertile Crescent region
Iraq
General population
Blood donors
Pregnant women
Children
Hemodialysis, renal
dialysis, and/or dialysis
patients
Hemophiliac or other
bleeding disorder patients
Transfused patients
Thalassemic patients
Patients with
hepatocellular carcinoma
Patients with acute liver
disease
Patients with chronic liver
disease
Healthcare workers
Barbers
Contact of patients with
hepatitis C
People who inject drugs
Prisoners
Patients with HIV and/or
other sexually transmitted
infection
Sex workers
Men who have sex with
men

Jordan

0.0%-4.0 % (2004-2012)1
No data
0.2%-2.8% (2003-2013)1 0.1%-0.9% (2003-2011)1
0.0%-5.1% (2004-2010)1
No data
0.0% (2007-2009)1
No data
4.9%-42.6% (2002-2011)1
21.0%-49.8%
(2003-2008)1

Lebanon

Palestine

Syria

0.6%-2.9% (-)2
0.0%-3.4% (< 2003)1
No data
No data
16.0%-27.0% (-)2

No data
0.2%-0.3% (2003-2013)1
No data
No data
17.9%-27.4%
(2007-2013)1

2.8% (2004)1
0.4% (2000-2011)1
No data
No data
21.0% (2006)1

6.7%-40.3% (2006-2012)1

No data

10.0% (-)3

No data

20.5% (2007-2011)1

3.4%-4.5% (2004-2008)1
4.0%-46.0% (2003-2012)1
26.1% (2000-2003)2

No data
32.8% (2008)1
No data

No data
0.0%-14.0% (> 1999)1
19.6% (1998-2003)2

No data
No data
No data

13.3% (2000)2
No data
No data

0.0%-71.9% (2007-2011)1

No data

No data

No data

1.0%(1995-1998)1

3.8%-62.0% (2005-2009)1

No data

No data

No data

No data

0.0%-9.1% (2002-2010)1
0.3% (1999-2001)1
1.2%-1.4% (1996-2001)1

0.7% (1999)1
No data
No data

0.4% (1999)1
No data
No data

No data
No data
No data

3.0%-3.8% (-)2
No data
No data

No data
0.6% (1996-2001)1
1.2% (-)2

No data
No data
No data

52.8% (2007-2008)1
3.4% (-)3
7.7% (-)3

45.2% (2010)1
No data
No data

60.5% (-)3
No data
No data

No data
No data

No data
No data

0.0% (2007-2008)1
0.0% (2007-2008)1

No data
No data

2.0% (-)2
No data

Prevalence, year of data collection. 1Good quality; 2Average quality; 3Poor quality.

[56]

AbbVie, and Bristol-Myers Squibb. Bruggmann et al
[50]
and Sievert et al
reported financial support from
Gilead Science, AbbVie, Merck, Bristol-Myers Squibb,
[56]
and Janssen Therapeutics. Bruggmann et al
had 34
authors who disclosed direct or indirect financial relation
ships with at least one of the HCV DAA pharmaceutical
companies (37% of the total number of authors).
Furthermore, six authors did not disclose their conflict
[50]
of interest. In Sievert et al , out of the 29 authors, 13
(45% of the total number of authors) disclosed direct
or indirect financial relationships with at least one of the
HCV DAA pharmaceuticals.
[6,56]
Interestingly, two
of the three SRs that reported
financial support from HCV DAA pharmaceutical
companies were published in 2014 and were the only
ones that estimated the total number of viremic cases
in the GP. They were also the only SRs that estimated
the genotype/subtype distributions in the GP of the
[43]
[50,55]
MENA region, except for Morocco , Pakistan
, and
[43]
Tunisia
where the distributions were also computed
by a couple of additional SRs. In Saudi Arabia, the third
SR estimating genotype/subtype distributions also
had authors who disclosed financial relationships with
[50]
HCV DAA pharmaceutical companies . Remarkably,
[6,56]
in both SRs
, the authors did not follow the PRISMA
[11]
guidelines (2009) for reporting their reviews in detail;
thus, we question the replicability of the reviews. Flow
diagrams depicting the numbers of records identified,
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included, excluded, and, most importantly, the reasons
[6,56]
for the exclusions were not presented in those SRs
.
[56]
Bruggmann et al
did not report the search criteria,
eligibility criteria, or the risk of bias assessment of
[56]
the included studies. Additionally, Bruggmann et al
reported that an expert panel reviewed the findings and
[6]
analysis, and Gower et al reported including “personal
communication with experts within countries”. However,
the authors did not report how they defined “expert”
[6,56]
or any conflicts of interest of these experts
. These
[6,56]
[56]
[6]
reviews
had been cited 185
and 890 times,
respectively, by February 12, 2018 (Google Scholar
citations) and published in journals with impact factors of
3.9 and 11.3 (in 2014), respectively.

HCV prevalence

In the GP, the estimations of the most up-to-date antiHCV prevalence with the best quality ranged widely
across MENA countries (Figure 2 and Tables 1-3).
We identified low prevalence (< 1.5%) in Djibouti,
Kuwait, Oman, Qatar, and UAE; moderate prevalence
(1.5%-3.5%) in Algeria, Iraq, Lebanon, Libya, Morocco,
Saudi Arabia, Sudan, Syria, and Tunisia; and high
prevalence (> 3.5%) in Egypt, Pakistan, and Yemen.
In Pakistan, anti-HCV prevalence may have increased
[62]
[6]
from 5.4% in 1996-2007
to 6.7%* in 2007-2008 .
No reported data in the GP was identified for Bahrain,
Jordan, or Palestine.
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Figure 2 Hepatitis C antibody prevalence evidence gap mapping with quality assessment, general population, MENA. MENA: Middle East and North Africa.

Summary points pertaining to the estimated antiHCV prevalences in blood donors, pregnant women,
children, and patients with acute liver disease or CLD
and HCC are highlighted in Supplementary Materials 8.
We identified that HCV transmission most likely
occurs in healthcare settings. In all 20 MENA countries,
patients with blood disorders such as hemophilia
and thalassemia, patients undergoing hemodialysis,
and patients who received transfusions had higher
prevalences of anti-HCV than the prevalence in the GP.
This suggests that transfusion-associated HCV infection
may have occurred in these patients (Supplementary
Material 8). Additionally, anti-HCV prevalences in
healthcare workers in Iraq, Libya, and Syria suggest
that in these countries, HCV transmission may also be
due to occupational exposure (Supplementary Material
8). Community-acquired HCV infection may also occur
in the MENA countries; however, we identified evidence
gaps in the region (Supplementary Material 8).
Anti-HCV prevalence measures were not often
identified for key populations such as PWID, prisoners,
and MSM. Anti-HCV prevalence data were predominantly
missing for the countries of the Arab Peninsula. No
reported data were identified for MSM, prisoners, or sex
workers in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia,
the UAE, or Yemen. For PWID, anti-HCV prevalence
data were identified in Egypt, Lebanon, Libya, Morocco,
Oman, Pakistan, Palestine, Saudi Arabia, Syria, and
Tunisia. For prisoners, reported anti-HCV prevalence data
were identified in Iraq, Lebanon, and Libya.
Sexual transmission may also be a cause of HCV
infection in some MENA countries. Anti-HCV prevalence
data in patients with HIV or other STDs were missing
for Algeria, Bahrain, Djibouti, Egypt, Jordan, Oman,
Pakistan, Palestine, Qatar, Syria, the UAE, and Yemen.
Anti-HCV prevalences in sex workers were reported for
a few countries.

in a population. Nevertheless, up-to-date incidence data
in MENA countries were lacking (Tables 4 and 5). In the
GP, the anti-HCV incidence rate was reported only in
Egypt, at 0.8-6.8 per 1000 person-year in 1997-2003.
The incidence rate was the highest in patients undergoing
hemodialysis in the UAE, at 108 per 1000 person-year in
2003-2004. The incidence rates in patients undergoing
hemodialysis were reported for Iraq, Jordan, Morocco,
Tunisia, and the UAE. These findings suggest ongoing
HCV transmission within healthcare settings in these
countries.

Viremic rate

In the GP, the HCV viremic rate among anti-HCV
positive individuals was 51.6%* (2011) in Saudi
[6]
[6]
Arabia ; approximatively 70%* in Egypt (2008) ,
[6]
Morocco (2005-2011) , and the UAE (study dates not
[6]
[6]
reported) ; 80.0%* (2012) in Tunisia ; and 87.4%*
[6]
(2007-2008) in Pakistan . Country-level HCV viremic
prevalences ranged between 0.7%* [95% confidence
[6]
interval (CI): 0.3%-3.8%, 2011] in Saudi Arabia and
[6]
10.0%* (CI: 7.0%-12.2%, 2008) in Egypt. The viremic
[6]
prevalence was 1.1%* (0.4%-1.4%, 2005-2011) in
[52]
Morocco, 1.0%* (0.2%-2.0%, 2012)
in Tunisia, and
[6]
5.8%* (1.4%-8.7%, 2007-2008) in Pakistan. In antiHCV positive blood donors, the viremic rate was 60.0%
[52]
in Libya (1992-2001)
and 20.0% in Saudi Arabia
[59]
(1988-2009) . In healthcare workers, the viremic
[52]
rate was reported in Libya as 69.2% (1992-2004) .
In dialysis patients, the HCV viremic rate was 51.0%
[52]
in Tunisia before 2000
and 60.5%-93.3% in
[52]
[52]
2000-2003 ; in Libya, it was 72.0% (before 2001) .
In HIV-infected patients in Morocco, the viremic rate was
[49]
reported as 70.4% (study dates not reported) .

Co-infection with hepatitis B virus, HIV, or
schistosomiasis
[36,47]

We identified two SRs
that reported HBV (HBsAg)
and anti-HCV co-infection prevalence estimates; these
estimates were only in HCC patients, and neither of

HCV incidence

The incidence rate reflects the status of HCV transmission

WJG|www.wjgnet.com

3045

July 21, 2018|Volume 24|Issue 27|

Chaabna K et al . HCV in the MENA region
Table 4 Hepatitis C antibody incidence and/or seroconversion risk rate relative to the total sample size, and evidence gap mapping,
Middle East and North Africa

Country
Algeria
Libya
Morocco
Tunisia
Djibouti
Sudan
Egypt

Pakistan

Systematic
review
Fadlalla,
2015[52]
Fadlalla,
2015[52]
Fadlalla,
2015[52]
Fadlalla,
2015[52]
Chaabna,
2016[27]
Chaabna,
2016[27]
Hussein,
2016[48]

Literature search
period

Number
Number of
of studies
subjects
identified

1980-Unknown

0

0

1980-Unknown

0

0

1980-Unknown

1

303

1980-Unknown

1

276

Inception-2015

0

0

Inception-2015

0

0

InceptionUnknown

-

-

Mohamoud,
2013[61]

InceptionUnknown

Mohamoud,
2013[61]
Mohamoud,
2013[61]
Sievert,
2011[50]
Sievert,
2011[50]

InceptionUnknown
InceptionUnknown

2

2852

3

10318

1

2177

Unknown

-

-

Unknown

0

0

Population
type

Hemodialysis
patients
Hemodialysis
patients

Children of
villages with
high HCV
prevalence
General
population
Pregnant
women
Pregnant
women

[36,47]

HCV seroHCV incidence
Duration of
Loss of
Estimation
conversion risk
rate (per 1000
follow-up
follow-up
time period
(%)
person-year)

2003-2004

97

-

-

-

2000-2002

28

-

-

-

-

6.9

-

-

-

2000-2006

2.7

-

-

-

1997-2003

0.8-6.8

-

-

-

1997-2006

5.2

-

-

-

-

5.2

-

-

-

these SRs
reported study dates/years. In Egypt,
Pakistan, Saudi Arabia, and Tunisia, the anti-HCV
prevalence was higher than the HBsAg prevalence,
while the opposite finding was observed in Lebanon,
Sudan, and Yemen (Supplementary Materials 9).
In Libya, 90.1% (CI: 78.2%-100%) of HIV-infected
prisoners had an HCV co-infection (study dates not
[49]
reported) . In HIV-infected children, the prevalence
[52]
of HCV co-infection was 43.0%-46.0% (1998-1999) .
The most up-to-date estimates of HCV co-infection
in HIV-infected patients were 5.4% (2006-2010) in
[52]
Morocco , 1.7% (CI: 0.2%-2.3%, study date not
[27]
reported) in Sudan , 33.5% (CI: 20.4%-46.6%,
[49,52]
1997-2005) in Tunisia
, and 7.7% (study dates not
[33]
reported) in Lebanon .
Studies on schistosomiasis and HCV co-infection
[45,61]
[27,45,46]
were reported for Egypt
, Sudan
, and Saudi
[59]
Arabia . In Egypt, 7.7%-84.0% (2002-2011) of the
[61]
schistosomiasis patients were also infected by HCV .
Prior to 2000, HCV prevalence in schistosomiasis
[61]
patients was 16.3%-42.5% . In Sudan, the prevalence
of schistosomiasis and HCV co-infection ranged from
[27]
[27]
4.5% to 31.0% in 2001 . In Saudi Arabia, 17.9% of
[59]
schistosomiasis patients were also infected with HCV .

No data in the GP was reported for Bahrain, Djibouti,
Oman, Qatar, or Yemen. In the other MENA countries it
[6,43,50,54,56]
was genotype 4 (45.2*-93.1%*)
(Supplementary
Materials 10 and 11). Interestingly, in Jordan, systematic
reviews reporting genotype 4 as the most common
genotype in the country had pooled estimates from
the GP and other at-risk populations. In Morocco and
Tunisia, subtype 1b was the most common genotype in
[43]
[50,55]
[50]
the GP , while in Pakistan
and Saudi Arabia , it
was 3a. In pregnant women, genotype 4 was reported
as the most common genotype in Algeria, Egypt, Iraq,
[44]
Libya, Saudi Arabia, Sudan, Tunisia, and Yemen ,
whereas genotype 1 was the most common genotype
[44]
[38]
in Morocco . Genotype distributions in blood donors
and in clinical populations, such as patients with CLD,
non-Hodgkin lymphoma, thalassemia, or hemophilia,
were similar to the distributions identified in the
[38,57]
general population
. However, in PWID in Saudi
Arabia, genotype 1 was reported as the most common
[50]
genotype (48%), followed by genotype 3 (36.0%*) ,
whereas in Lebanon, genotype 3 was the most common
genotype (26.3%-57.0%), followed by genotype 1
[38]
(21.0%-42.1%) and genotype 4 (18.0-34.6) .

HCV genotype and subtype

The risk factors for acquiring an HCV infection reported
for MENA countries were factors associated with medical
practices (blood transfusion, catheter use, hemodialysis,
nosocomial exposure, and invasive procedures, among
[27,39,40,44,45,50,52,53,57,59-61]
others)
(Supplementary Material 12).

Risk factors associated with HCV infection

In the GP, genotype 1 was the most common genotype
[6]
[6,43]
in Algeria (69.2%*) , Morocco (75.9%)
, Tunisia
[6,43]
[6]
(84.0%) , and Jordan (73.3%*) , while in Pakistan the
[40]
most common genotype was genotype 3 (67.5%-86.7%) .
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Table 5 Hepatitis C antibody incidence and/or sero-conversion risk rate relative to the total sample size, and evidence gap mapping,
Middle East and North Africa

Country
Iraq

Number
Number of
Systematic Literature search
of studies
subjects
period
review
identified
Chemaitelly,
1985-2015
1
57
2015[33]
Chemaitelly,
2015[33]

1985-2015

1

123

Chemaitelly,
2015[33]

1985-2015

1

26

Chemaitelly,
2015[33]

1985-2015

1

85

Chemaitelly,
2015[33]

1985-2015

1

60

Chemaitelly,
2015[33]

1985-2015

1

29

Chemaitelly,
2015[33]

1985-2015

1

27

0

0

0

0

1

1300

0

0

0

0

1

-

0

0

Chemaitelly,
1985-2015
2015[33]
Chemaitelly,
Palestine
1985-2015
2015[33]
Chemaitelly,
Jordan
1985-2015
2015[33]
Bashour,
Syria
Unknown
2016[91]
Sievert,
Unknown
2011[50]
United
Mohamoud,
Arab
Unknown
2016[59]
Emirates
Chaabna,
Yemen
Inception-2015
2016[27]
Lebanon

Population type
Hemodialysis
patients
Pediatric patients
with acute
lymphoblastic
leukemia
Newborn to HCV
infected women
Pediatric cancer
patients on
chemotherapy

2009

-

0

40.3

12 mo

2007

-

0

3.2

30 mo
(median)

-

-

0

0

6 mo

2006-2007

-

22

3.2

12 mo

2007-2009

-

0

0

6 mo

2007-2009

-

0

3.5

6 mo

2007-2009

-

0

0

6 mo

Hemodialysis
patients

2003

-

-

9.2

12 mo

Hemodialysis
patients

1995

108

-

-

-

Healthy children
Pediatric patients
with leukemia on
chemotherapy
Pediatric patients
with leukemia
who have had
their baseline
screening prior to
chemotherapy

These risk factors suggest that iatrogenic transmission
[39,44,45,50,60,61]
[44]
is specifically found in Egypt
, Iraq ,
[40,50,53,57]
[50]
[44,45]
[50]
Pakistan
, Saudi Arabia , Sudan
, Syria ,
[44]
and Yemen . In Egypt, Pakistan, Saudi Arabia, Sudan,
and Syria, factors associated with the community were
also reported (contacts of HCV-infected patients, sharing
razors, circumcision, injection from informal health
[39,40,44,45,50,53,57,60,61]
provider, and tattooing, among others)
.
[45,59,61]
[44]
Age
, level of education in Yemen , intravenous
[57]
[50]
drug use in Pakistan and Syria , and homosexuality
[57]
in Pakistan were also associated with HCV infection.

reported them and emphasized the opportunities for
further population health research to better characterize
HCV epidemiology in the region.

Quality assessment

Our overview of SRs identified that a substantial
proportion of SRs on HCV epidemiology in MENA
failed to report their outcomes following the PICOTS
[25,26]
framework
. This can potentially lead to imprecise
reported information that can, in turn, mislead data
[26]
interpretation . In addition to providing accurate
information on HCV epidemiology, outcomes should
also demonstrate practical and clinical significance and
relevance. While most SRs of clinical research were
determined to not be useful because their conclusions
[66]
were false or exaggerated , it appears that we should
also question the usefulness of SRs of population health
research on HCV epidemiology in the MENA region. The
SRs of HCV epidemiology in the MENA region stated that
their aim was to provide a clear picture of the situation
in the region. However, a substantial proportion of the

DISCUSSION
Stretching from North Africa through the Middle East
and into central Asia, the MENA region demonstrates
a wide range of anti-HCV and viremic prevalences and
diversity in HCV genotype distributions. For each country,
our mapping of evidence gaps and quality assessment
of outcomes reported on the available HCV morbidity
measurements, their quality, and how well the SRs

WJG|www.wjgnet.com

HCV seroHCV incidence
Duration of
Loss of
Estimation
conversion risk
rate (per 1000
follow-up
follow-up
time period
(%)
person-year)
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SRs in our overview lacked the key identified features of
transparency (“are methods, data, and analyses verifiable
[66]
and unbiased?” ) and pragmatism (“inferences should
[66]
be applicable to real-life circumstances” ), which also
[66]
are lacking in clinical research .
To reach the Global Health Sector Strategy on Viral
[67]
Hepatitis (GHSS-VH) 2030 elimination goal , SRs
of HCV epidemiology should assist policymakers in
developing treatment programs and effective, precise
prevention strategies for micro-elimination targeting
specific populations at higher risk of acquiring HCV
infections. Additionally, SRs of HCV epidemiology should
guide changes to make clinical practices safer. Hence, an
accurate picture is not obtainable by pooling population
estimates of groups at different risk of acquiring HCV
infections, such as patients undergoing hemodialysis
combined with PWID, MSM combined with healthcare
workers, or the GP combined with blood donors.
Furthermore, estimated HCV outcomes should be as
up-to-date as is reasonably possible, encompassing a
narrow interval of time to attempt to depict the current
situation in the region. The outcomes can be pooled
by period, so potential changes in the epidemiological
profile can be demonstrated. As such, dissemination of
pooled estimates that combine data from many studies,
some conducted two decades ago, in order to increase
the statistical power does not appear to be useful in
nowcasting the epidemiology of HCV in the region and
is not helpful in developing effective preventive and
treatment programs essential to attaining the 2030 HCV
infection elimination goal.

manifestations of HCV-related hepatic and extra-hepatic
[69]
dysfunctions occur , which may then lead to the
diagnosis of HCV infection. The distributions of these
dysfunctions and diseases reflect past HCV infection
[69,70]
transmission
. Hence, the prevalence of anti-HCV
provides a retrospective snapshot of HCV transmission
in a population, while the incidence describes the
current HCV status in that population. Our overview
also identifies research evidence gaps pertaining to upto-date anti-HCV incidence data in all MENA countries.
Therefore, we recommend that additional research be
conducted to measure the HCV incidence to assess
current HCV transmission trends. Incidence studies
in the GP and populations at differing levels of risk for
acquiring HCV will allow real-time measurement of
HCV transmission. Nowcasting will help policymakers to
develop and implement efficient prevention strategies
alongside treatment programs.

Status of HCV epidemiology in the MENA region:
Prevalence in the general population

Among the 20 MENA countries, anti-HCV prevalence in
the GP varied widely. Egypt, Pakistan, and Yemen were
classified as having high prevalences of anti-HCV. In
the six Gulf Nations, namely, Bahrain, Kuwait, Oman,
Qatar, Saudi Arabia, and the UAE, the reporting quality
of the anti-HCV prevalence data was poor (no data
for Bahrain). Nevertheless, the available data in the
GP demonstrate low-to-moderate prevalences of antiHCV in these countries. Remarkably, in these countries,
the data from blood donors were of better reporting
quality. Among blood donors, the anti-HCV prevalence
was lower in nationals than in migrants, suggesting that
the demographic characteristics of these Gulf Nations
(nationals vs migrants) should be considered when
[71]
describing the HCV epidemiology . In these countries,
population size increased rapidly in the last two decades
[72]
due to the immigration of temporary workers . More
than 30% of the populations of the Gulf Nations are
migrants; in Qatar and the UAE in 2014, this figure
[73,74]
was over 80%
. In Qatar, Egyptian and Pakistani
migrants accounted for 9% and 5% of the population,
respectively, while Qatari nationals accounted for 12%
[75]
(2016) . HCV prevalence in a GP including both
nationals and migrants in a country such as Qatar will
be influenced by the HCV epidemiology profiles of the
migrants’ countries of origin. Of note, migrants have
to be negative for HIV, HBV, and HCV upon arrival in
the Gulf Nations; however, screening is not mandatory
thereafter, except for some professions such as those in
[76-81]
the healthcare sector
. Thus, HCV-infected migrants
in these countries would most likely have been infected
while visiting their countries of origin.

Conflict of interest

The evaluation of SRs should not be limited to the
assessment of the reported methods, assumptions,
[31]
data, and results . Our overview emphasizes the
significance of considering the disclosure of financial
[31]
relationships while assessing research . Researchers
can be influenced by financial relationships while
making judgments and decisions at a subconscious level
[31]
such that they are not aware of the influence . In the
era of DAA treatment, the only published SRs providing
the number of chronically HCV-infected individuals in
the MENA region have substantial proportions of their
authors who disclosed financial relationships with HCV
DAA pharmaceutical companies. Our overview iden
tifies a need in the MENA region for estimates of the
number of chronically HCV-infected individuals who are
candidates for DAA treatment by researchers who have
not received financial assistance from Gilead Science.

Status of HCV epidemiology in the MENA region:
Incidence

HCV infection is usually a slow progressive disease,
which can lead to liver cirrhosis a couple of decades
[68]
post-HCV infection . Patients with liver cirrhosis are
at 1%-5% annual risk of HCC and a 3%-6% annual
[68]
risk of hepatic decompensation . As such, a long
period with non-specific symptoms passes before
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Status of HCV epidemiology in MENA: Prevalence in
blood donors

In countries that (1) prohibit persons at higher risk of
acquiring blood-borne infection from donating blood and
(2) systematically implement pre-transfusion screening
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of blood donation for these infections, the prevalence of
blood-borne infections in blood donors should be lower
[28,29]
than that in the GP
. In some MENA countries, the
anti-HCV prevalence was higher in blood donors than
in the GP. Furthermore, in MENA countries, prevalence
and incidence measurements in transfused patients
and in patients with blood disorders suggest that HCV
transmission in healthcare settings is prevalent and
is likely to be ongoing. There is a need to ensure that
patients receive the safest possible blood products. The
management of all blood units and their components
should guarantee that only those with negative HCV
screening assays are sent to the hospitals to be used
in transfusions. Strong regulatory policies for all blood
banks must be implemented and enforced to achieve
this.

HIV positive prisoners. Similarly, HCV epidemiology in
MSM was described only in Sudan and Lebanon, and no
data from HIV-infected MSM were identified. Lebanon,
Libya, Sudan, Syria, and Tunisia reported higher antiHCV prevalences in female sex workers than in the
GP, demonstrating that this population may be at
higher risk of acquiring HCV infections. Consequently,
population health research studies are needed in these
key populations to comprehensively characterize HCV
epidemiology in the MENA countries, which will facilitate
better planning, development, and implementation of
precise preventive strategies and treatment programs.

Status of HCV epidemiology in the MENA region:
HBV and HIV co-infection, vertical transmission, and
community

Co-infections with HCV and HBV or HIV, which share
common modes of transmission, namely, through
[86]
exposure to infected blood and sexual transmission ,
reminds us of the need for a holistic approach to tackle
the population health issue of blood-borne infections.
Additionally, the identified evidence regarding HCV
morbidity (incidence and prevalence) in pregnant
women and in children in Egypt, Pakistan, Saudi Arabia,
and Yemen suggested that vertical HCV transmission
may also occur. As for vertical transmission, little
evidence was identified regarding community-acquired
HCV infections. Additional research studies are needed
to explore these transmission modes.

Status of HCV epidemiology in the MENA region:
Prevalence in healthcare settings

In Pakistan, HCV transmission due to unsafe injections
(i.e., using contaminated needles and syringes) was
[82]
identified in 2000 , and in 2006, the proportion of
people sharing injection equipment during their last
[83]
injection was between 8.5% and 33.6% , suggesting
that HCV transmission in healthcare settings was still
ongoing. Additionally, we report that the prevalence of
anti-HCV is higher in healthcare workers than in the
GP in Iraq (2002-2010), Libya (1992-2004), Syria,
and Yemen (study dates not reported). In 1999, HCV
transmission in healthcare workers due to needle
injuries from HCV-positive patients was reported in
[84]
Pakistan . The identified evidence suggests that
occupational exposure to HCV occurs in healthcare
settings in some MENA countries. In 2000, in order
to prevent the transmission of HCV and other bloodborne infections in healthcare settings, the World Health
Organization recommended the implementation of
strategies targeting healthcare workers and patients,
focusing on achieving behavioral changes to reduce reuse and over-use of injections, increase the exclusive
use of sterile syringes and needles, and increase the
[85]
proper disposal of sharp waste after use .

Status of HCV epidemiology in the MENA region:
Genotype geographical pattern

Genotype/subtype 1b is omnipresent across the region.
Genotype 4 appears to be the most common in Egypt.
In the Gulf Nations, the dominance of genotype 4 might
be explained by the high proportion of migrants from
Egypt. Genotype 3 is the most common in Pakistan,
suggesting that intravenous drug use is likely the driver
[87,88]
of HCV transmission in this country
. Genotype 3a in
[88]
Pakistan appears to have emerged around the 1920s .
Many SRs reported HCV genotype/subtype distri
butions and pooled frequencies without specifying the
temporality of their identified geographical pattern. HCV
genotypes differ according to the mode of transmission.
For instance, while HCV-1b is the most prevalent HCV
[6]
genotype/subtype globally , HCV-3 and 1a are linked to
[87]
PWID, and in Asia, HCV-1a is also linked to PWID . A
birth cohort analysis demonstrated that the distribution
of HCV genotypes is changing in Japan and appears to
be associated with the establishment of the prevention
of HCV transmission through blood transfusions or
[89]
nosocomial infections in 1990 . In Japan, genotype
1b is associated with the former mode of transmission,
while genotypes 2a and 2b are associated with the latter
[89]
mode of transmission . Unfortunately, because of how
genotype/subtype data are pooled and reported for the
MENA region, we were not able to identify differences in
time trends and geographic patterns.

Status of HCV epidemiology in the MENA region: Key
populations

Intravenous drug use appears to drive HCV infection
in half the MENA countries, namely, Egypt, Lebanon,
Libya, Morocco, Oman, Pakistan, Palestine, Saudi
Arabia, Syria, and Tunisia. Relatively up-to-date data
with good reporting quality were identified for these
countries. However, missing data for the other MENA
countries impact the evaluation of role of intravenous
drug use in HCV transmission in a substantial part
of the region. Prisoners are a key population rarely
studied in MENA countries. We identified HCV outcomes
in prisoners in only three countries (Libya, Iraq, and
Lebanon). It appears that incarcerated individuals are
at higher risk of acquiring HCV infections, especially
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Quality assessment, strengths and limitations of our
overview

based policies should be established from up-to-date
information generated from rigorously designed studies
and reported outcomes.
Our synthesis of the published SRs of HCV epide
miology in the MENA region demonstrates that despite
the region being recognized as having the greatest
HCV burden, a majority of the 20 countries have
low to moderate anti-HCV prevalence. Only Egypt,
Pakistan, and Yemen demonstrated a high anti-HCV
prevalence. Iatrogenic transmission of HCV in patients
and occupational exposure in healthcare workers are
likely to be ongoing in the MENA countries. There
is an urgent need for safer blood products and the
implementation of safe medical practice guidelines.
Intravenous drug use appears to be another common
mode of HCV transmission in half the MENA countries.
Research studies are needed to characterize the status
of HCV epidemiology in PWID in countries where data
are lacking. To develop effective prevention strategies
and treatment programs to achieve HCV elimination,
characterizing HCV epidemiology in key populations
such as MSM and sex workers is essential and cannot be
overlooked.

[11-13]

We followed PRISMA guidelines
in reporting our
work. All PRISMA required items regarding the abstract
and the different sections of the main text were
reported. Furthermore, we assessed our methodology
[14]
using the AMSTAR tool . We answered eight of the 11
questions of this tool in the affirmative and reported the
pages where the information can be found. The three
remaining questions were not applicable to our work
(e.g., “Were the methods used to combine the findings
[14]
of studies appropriate ? Was not applicable because
we did not conduct a meta-analysis).
The quality assessment of SRs we conducted was
limited to all SRs of HCV epidemiology in the MENA
region that were published in peer-reviewed journals
indexed on Medline as identified through PubMed, which
may not be representative of SRs of HCV epidemiology
in the MENA region in general. However, PubMed has
been recognized as the first public digital archive; as
such, we can assume that we have assessed the quality
of the majority of SRs of HCV epidemiology published
[90]
in peer-reviewed journals . Additionally, we critically
synthesized all available data on HCV morbidity and risk
factors reported by those SRs. Knowing that most of
the 37 SRs included in our overviews conducted a multisource literature search including, in some SRs, a search
for gray literature, we assumed that our synthesis in
this overview is comprehensive. However, we might
have missed some studies published recently that were
not included in the SRs included in our overview. For
instance, in Egypt, anti-HCV prevalence was estimated
[5]
to be 6% in 2014 , yet none of the SRs we included
reported that estimate.

ARTICLE
ARTICLEHIGHLIGHTS
HIGHLIGHTS
Research background

The Middle East and North Africa (MENA) has been identified as the region
most affected by hepatitis C virus (HCV) infection worldwide predominantly due
to the high HCV infection burden in Egypt and Pakistan. Since 2013, chronic
infections with HCV genotypes 1, 2, 3, and 4 are curable, making elimination of
HCV infection achievable for the first time. However, access and availability of
the new direct-acting antiviral drug (DAA) regimens remains a challenge owing
to country-level economic matters.

Research motivation

Developing and prioritizing evidence-based strategies for prevention programs
and treatment scale-up require up-to-date information generated from rigorously
designed studies and reported outcomes. A substantial number of systematic
reviews of HCV infection in the MENA region have been published. What is
the quality of these systematic reviews and what is the quality of the studies
included in these systematic reviews? Researchers can be influenced by
financial relationships while making judgments and decisions at a subconscious
level such that they are not aware of the influence. The use and interpretation
of the outcomes in the systematic reviews need to be viewed keeping in mind
the reported conflict of interests by the authors of the systematic reviews. Our
overview was also motivated because of the following questions: what do we
know about hepatitis C epidemiology in the MENA region? High country-level
anti-HCV prevalence has been identified in Egypt and Pakistan. What is the
status of the other 18 MENA countries? What are the identified potential modes
of transmission and populations at higher risk of acquiring hepatitis C infection?

CONCLUSION
To reach the 2030 HCV infection elimination goal set by
[67]
the GHSS-VH , evidence-based health policies need to
be developed and implemented to optimize the allocation
of financial resources and to alleviate the burden of
disease due to HCV infection. Correct measures of antiHCV prevalence, viremia, and genotype distribution
are essential for developing strategies to manage and
eliminate HCV infection. Evidence gap mapping and
quality assessment, along with reviewing reported
conflicts of interest, revealed countries and specific
populations where data are scarce and/or lacking in
quality. We identified areas of opportunity to further
develop population health research to comprehensively
characterize HCV infection in the MENA region. Currently,
the available estimates of the numbers of chronically
HCV-infected patients who are candidates for the
new DAA regimens are computed by researchers, a
substantial proportion of whom have indirect or direct
financial relationships with HCV DAA pharmaceutical
companies. Additionally, a substantial proportion of the
included SRs did not report precise outcomes, which
can lead to misinterpretation of the data. Evidence-
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Research objectives

The primary objective of our overview is to assess the quality of the data
reported by the published systematic reviews of HCV epidemiology in the
MENA countries taking into account conflict of interest disclosed by the
authors of these systematic reviews. Our secondary objective is to produce a
comprehensive picture of HCV infection epidemiology in the 20 countries of the
MENA region.

Research methods

An a priori protocol of our overview is registered with the International
Prospective Register of Systematic Reviews (PROSPERO registration number
CRD42017076736). We conducted an overview of systematic reviews based
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on the Cochrane Handbook for Systematic Reviews of Interventions. We
used broad search criteria to include all systematic reviews on HCV infection
in the MENA region published after 2008 - the publication year of the first
version of the Cochrane Handbook for Systematic Reviews of Interventions.
We extracted all relevant outcomes related to HCV infection epidemiology.
The nine primary outcomes of interest were HCV antibody (anti-) prevalences
and incidences in different at-risk populations; the HCV viremic (RNA positive)
rate in HCV-positive individuals; HCV viremic prevalence in the general
population; the prevalence of HCV co-infection with the hepatitis B virus,
human immunodeficiency virus, or schistosomiasis; the HCV genotype/subtype
distribution; and the risk factors for HCV transmission. Thereafter, we critically
analyzed and synthesized the extracted data by assessing their quality using PICOTS framework, by evaluating conflict of interests disclosed by the
authors of the systematic reviews, and by mapping the evidence and the gaps.
Our overview is reported following PRISMA guidelines and assessed using
AMSTAR tool.

quality data are required in order to nowcast HCV epidemiology in the region.
When data is available for long time periods, reporting should reflect changes
in prevalence or incidence over time, which will allow to accurately describe the
past and current HCV epidemiology in a population.
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